Daily Ards Research Analysis
Analyzed 5 papers and selected 3 impactful papers.
Summary
Mechanistic and translational advances in ALI/ARDS dominate today’s findings. Nebulized hUCMSC-derived exosomes protect pulmonary endothelium by upregulating RPS11 to restore mitochondrial translation and inhibit ferroptosis, while S100A9 lactylation and GBP5-driven inflammasome signaling illuminate immunometabolic control of sepsis-related lung injury.
Research Themes
- Exosome-based inhaled therapies targeting endothelial mitochondrial homeostasis
- Immunometabolism and protein lactylation driving macrophage inflammatory programs
- Inflammasome–adenosine signaling feedback in acute lung injury
Selected Articles
1. hUCMSC-exosomes attenuate acute lung injury by inhibiting ferroptosis in pulmonary microvascular endothelial cells through ribosomal protein RPS11 upregulation.
Using a nebulized LPS-ALI model, inhaled hUCMSC-exosomes entered pulmonary microvascular endothelial cells, restored mitochondrial function by enhancing mitochondria-encoded protein translation via RPS11 upregulation, and inhibited ferroptosis, resulting in reduced edema, inflammation, and histologic injury.
Impact: Demonstrates a noninvasive, cell-free therapy that directly targets endothelial mitochondrial homeostasis and ferroptosis, supported by mechanistic multi-omics and functional validation.
Clinical Implications: Supports development of inhaled exosome therapeutics for ALI/ARDS, with RPS11 as a putative pharmacodynamic marker and ferroptosis/mitochondrial endpoints to guide early-phase trials and dosing strategies.
Key Findings
- Nebulized hUCMSC-exosomes are internalized by pulmonary microvascular endothelial cells and alleviate LPS-induced ALI.
- Exosomes reduce ferroptosis and improve mitochondrial function by transferring mitochondrial components and upregulating RPS11.
- RPS11 is necessary for the anti-ferroptotic and mitochondrial rescue effects; its knockdown abrogates exosome benefits.
- Mechanism involves enhanced translation of mitochondria-encoded proteins.
Methodological Strengths
- Nebulized ALI model with high homogeneity and endothelial targeting
- Mitochondrial proteomics and multi-omics validation across models
- Functional necessity shown via RPS11 knockdown
- Consistent in vitro confirmation in human pulmonary microvascular endothelial cells
Limitations
- Preclinical models without human clinical data
- Potential variability in exosome preparations and dosing
- Long-term safety and repeated inhalation effects are unknown
Future Directions: Standardize exosome manufacturing and dosing for inhalation, validate RPS11 as a pharmacodynamic/response biomarker in large animals and early human trials, and compare against standard-of-care ventilation strategies.
BACKGROUND: Human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) are a promising treatment for acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), but traditional delivery methods have limitations. Therefore, this study presents a noninvasive therapeutic approach for ALI/ARDS, offering new mechanistic insights and identifying potential therapeutic targets. RESULTS: We established a nebulized LPS-induced ALI model that was characterized by diffuse lung injury and high homogeneity. Following inhalation, hUCMSC-Exos were observed to be internalized by pulmonary microvascular endothelial cells. Analysis revealed that hUCMSC-Exos alleviated ALI by reducing the severity of histological damage, pulmonary oedema, lung inflammation and ferroptosis. Additionally, hUCMSC-Exos improved the mitochondrial function of human pulmonary microvascular endothelial cells (HPMECs) via the transfer of mitochondrial components. Subsequent proteomic sequencing of mitochondria isolated from HPMECs receiving different treatments revealed the significant differential expression of ribosomal proteins among the groups. The most significantly upregulated protein, RPS11, was identified as a key mediator; its knockdown blocked the ability of hUCMSC-Exos to suppress ferroptosis and restore mitochondrial function in HPMECs. Mechanistically, hUCMSC-Exos exert their effects by enhancing mitochondria-encoded protein translation. CONCLUSIONS: We report a mechanism whereby hUCMSC-Exos upregulate RPS11 to promote mitochondria-encoded protein translation, rescuing mitochondrial function, inhibiting ferroptosis in HPMECs, and ultimately alleviating ALI. Validated across multiple models and supported by multi-omics analyses, our findings collectively establish nebulized hUCMSC-Exos as a promising cell-free therapy targeting mitochondrial homeostasis in HPMECs for the treatment of ALI.
2. S100A9 lactylation facilitated sepsis-related acute respiratory distress syndrome via promoting transcription activation of IL-1β in macrophages.
S100A9 undergoes lactylation at K4 and K94 in sepsis, which drives its nuclear translocation and interaction with C/EBPβ to activate IL-1β transcription in macrophages, exacerbating sepsis-related ALI/ARDS. Genetic ablation of S100A9 mitigates inflammation and lung injury, highlighting a modifiable immunometabolic pathway.
Impact: Links protein lactylation to macrophage transcriptional control and sepsis lung injury with defined sites (K4/K94), offering concrete nodes for therapeutic targeting.
Clinical Implications: Suggests therapeutic strategies targeting S100A9 lactylation, nuclear translocation, or downstream IL-1β signaling; lactylation status could serve as a biomarker to stratify patients with sepsis-related ALI/ARDS.
Key Findings
- S100A9 is lactylated at K4 and K94 in septic patients and CLP mice.
- Lactylated S100A9 translocates to the nucleus and enhances interaction with C/EBPβ.
- The S100A9–C/EBPβ complex activates IL-1β transcription, promoting sepsis-related ALI.
- S100A9 knockout alleviates sepsis-induced inflammation and lung injury.
Methodological Strengths
- Identification of post-translational modification sites by immunoprecipitation and mass spectrometry in human and mouse samples
- Mechanistic validation using mutagenesis, co-immunoprecipitation, and luciferase reporter assays
- Integration of patient-derived data with in vivo CLP sepsis models
Limitations
- Preclinical mechanistic study without interventional validation in humans
- Lack of a selective pharmacologic inhibitor to directly modulate S100A9 lactylation in vivo
- Sample sizes for human cohorts not detailed in the abstract
Future Directions: Develop small molecules or biologics to inhibit S100A9 lactylation or nuclear translocation, test IL-1β pathway modulation in sepsis-ALI models stratified by S100A9 lactylation, and assess lactylation as a biomarker in prospective cohorts.
BACKGROUND: Sepsis is a severe inflammatory condition often complicated by acute lung injury (ALI) with limited therapeutic options. S100 Calcium Binding Protein A9 (S100A9) as an alarmin is highly elevated in sepsis. We observed that S100A9 was lactylated in the lung tissues of septic mice, the role of which in regulating sepsis-related ALI remains unknown. METHODS: S100A9 lactylation sites were identified in septic patients and CLP mice using immunoprecipitation and mass spectrometry. Mechanistic studies employed mutagenesis, co-immunoprecipitation, and luciferase assays. RESULTS: In this study, we confirmed that S100A9 was lactylated at K4 and K94 in septic patients. Lactylated S100A9 promoted its nuclear translocation, thereby enhancing its interaction with transcription factor CCAAT/enhancer-binding protein beta (Cebpb). The complex of S100A9 and Cebpb further promoted the transcriptional activation of downstream interleukin 1 beta (IL-1β), leading to sepsis-related ALI. Moreover, the knockout of S100A9 effectively alleviated sepsis-induced inflammatory response and lung injury. CONCLUSIONS: Our findings elucidated the importance of S100A9 lactylation in regulating inflammatory responses of macrophages in sepsis-induced ALI, providing novel insights into the pathophysiology of sepsis and potential therapeutic targets for sepsis-associated organ dysfunction.
3. GBP5 Aggravates Acute Lung Injury Via NLRP3 Inflammasome Activation While Inducing a HIF-1α-CD73-adenosine Feedback Loop.
GBP5 amplifies ALI via NLRP3 inflammasome activation but concurrently induces a compensatory HIF-1α–CD73–adenosine–cAMP–CREB loop that restrains excessive inflammation. AAV-mediated GBP5 knockdown attenuated lung injury and cytokine release, while mechanistic assays confirmed HIF-1α-dependent CD73 upregulation and downstream anti-inflammatory signaling.
Impact: Reveals a dual-edged role of GBP5 in ALI, integrating inflammasome activation with an adenosine-mediated negative feedback loop, which refines therapeutic targeting strategies.
Clinical Implications: Therapies modulating GBP5/NLRP3 may attenuate injury but must account for the protective HIF-1α–CD73–adenosine loop; combinatorial approaches could balance pathogen clearance and inflammation control in ALI/ARDS.
Key Findings
- LPS-induced lung injury upregulates GBP5 and adenosine metabolism genes.
- AAV-mediated intratracheal GBP5 knockdown (n=10/group) reduces NLRP3 inflammasome activation and inflammatory cytokines, mitigating ALI.
- GBP5 overexpression increases CD73 via HIF-1α-dependent transcription; CD73 promotes cAMP/p-CREB signaling and suppresses NLRP3.
- Defines a GBP5-driven proinflammatory pathway with a concurrent compensatory HIF-1α–CD73–adenosine feedback loop.
Methodological Strengths
- In vivo AAV-mediated gene knockdown with phenotypic and molecular readouts
- Transcriptomic profiling (RNA-seq) to map pathway changes
- Mechanistic confirmation using dual-luciferase reporter assays and in vitro macrophage models
Limitations
- Single acute LPS model and male mice limit generalizability
- No pharmacologic modulation of GBP5 or adenosine signaling tested in vivo
- Lack of validation in human tissues
Future Directions: Evaluate pharmacologic GBP5/NLRP3 inhibitors with or without adenosine pathway agonism, validate the feedback loop in infectious and sterile ALI models, and assess CD73/ADORA2A as biomarkers in translational studies.
Guanylate-binding protein 5 (GBP5) is an interferon-inducible GTPase that promotes NLRP3 inflammasome activation. However, its role in acute lung injury (ALI) and its relationship with compensatory anti-inflammatory pathways remain poorly defined. Methods: We employed an LPS-induced ALI mouse model with AAV-mediated intratracheal GBP5 knockdown, transcriptomic profiling (RNA-seq), and in vitro studies in THP-1 macrophages. GBP5 overexpression and CD73 overexpression were used to dissect the GBP5-HIF-1α-CD73-adenosine axis. RNA-seq analysis of LPS-induced lung injury revealed upregulation of GBP family members (particularly GBP5) and multiple adenosine metabolism genes. AAV-mediated GBP5 knockdown in male C57BL/6 mice (6-8 weeks, n = 10/group) attenuated LPS-induced lung injury, reduced NLRP3 inflammasome activation (NLRP3, ASC, cleaved caspase-1), and decreased inflammatory cytokine levels (IL-1β, IL-6, TNF-α). In parallel, GBP5 knockdown suppressed CD73 and ADORA2A expression, whereas GBP5 overexpression in THP-1 macrophages enhanced CD73 expression via HIF-1α-dependent transcriptional activation confirmed by dual-luciferase reporter assays. CD73 overexpression in turn elevated cAMP/p-CREB signaling and suppressed NLRP3 inflammasome activity. GBP5 exacerbates ALI through NLRP3 inflammasome activation while simultaneously driving a compensatory HIF-1α-CD73-adenosine-cAMP-CREB feedback loop that restrains excessive inflammation. Targeting this dual pathway may offer novel therapeutic strategies for ALI and ARDS.